Oxido-reductive regulation of vascular remodeling by receptor tyrosine kinase ROS1

Journal of Clinical Investigation

Volumn 124, Issue 12, 2014, Pages 5159-5174

  Ali, Ziad A ^a,b,c   De Perez, Vinicio Jesus ^a   Yuan, Ke ^a   Orcholski, Mark ^a   Pan, Stephen ^a   Qi, Wei ^b   Chopra, Gaurav ^d   Adams, Christopher ^a   Kojima, Yoko ^a   Leeper, Nicholas J ^a   Qu, Xiumei ^a   Zaleta Rivera, Kathia ^a   Kato, Kimihiko ^e   Yamada, Yoshiji ^e   Oguri, Mitsutoshi ^f   Kuchinsky, Allan ^a   Hazen, Stanley L ^g   Jukema, J Wouter ^h   Ganesh, Santhi K ⁱ   Nabel, Elizabeth G ^j   Channon, Keith ^k   Leon, Martin B ^b,c   Charest, Alain ^l   Quertermous, Thomas ^a   Ashley, Euan A ^a   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^d STANFORD UNIVERSITY   (United States)

^e MIE UNIVERSITY   (Japan)

^f JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^g LERNER RESEARCH INSTITUTE   (United States)

^h ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k UNIVERSITY OF OXFORD   (United Kingdom)

^l TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; GLUTATHIONE; GLUTATHIONE PEROXIDASE 1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; RECEPTOR TYROSINE KINASE ROS1; UNCLASSIFIED DRUG; GLUTATHIONE PEROXIDASE; MUSCLE PROTEIN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; ROS1 PROTEIN, HUMAN; ROS1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MALE; MOUSE; NEOINTIMA; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER; STENT THROMBOSIS; VASCULAR DISEASE; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE; AMINO ACID SUBSTITUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; MISSENSE MUTATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOLOGY;

AMINO ACID SUBSTITUTION; ANIMALS; ATHEROSCLEROSIS; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUTATHIONE PEROXIDASE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; MUTATION, MISSENSE; MYOCYTES, SMOOTH MUSCLE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; VASCULAR REMODELING;

EID: 84915820737     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI77484     Document Type: Article

References (54)

1. Go AA, et al. Heart disease and stroke statistics - 2014 update: A report from the American Heart Association. Circulation. 2014;129(3):e28-e292.
2. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol. 1990;15(7):1667-1687.
3. Weisz G, et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol. 2009;53(17):1488-1497.
4. Finn AV, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27(7):1500-1510.
5. Ali ZA, et al. Increased in-stent stenosis in ApoE knockout mice: insights from a novel mouse model of balloon angioplasty and stenting. Arterioscler Thromb Vasc Biol. 2007;27(4):833-840.
6. Blankenberg S, et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med. 2003;349(17):1605-1613.
7. Lapenna D, et al. Glutathione-related antioxidant defenses in human atherosclerotic plaques. Circulation. 1998;97(19):1930-1934.
8. Forgione MA, et al. Heterozygous cellular glutathione peroxidase deficiency in the mouse: abnormalities in vascular and cardiac function and structure. Circulation. 2002;106(9):1154-1158.
9. Galasso G, et al. Impaired angiogenesis in glutathione peroxidase-1-deficient mice is associated with endothelial progenitor cell dysfunction. Circ Res. 2006;98(2):254-261.
10. Torzewski M, et al. Deficiency of glutathione peroxidase-1 accelerates the progression of atherosclerosis in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27(4):850-857.
11. Lewis P, et al. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein e-deficient mice. Circulation. 2007;115(16):2178-2187.
12. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):154-160.
13. Lange H, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004;350(26):2673-2681.
14. Ashley EA, et al. Network analysis of human in-stent restenosis. Circulation. 2006;114(24):2644-2654.
15. Schwartz RS, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19(2):267-274.
16. Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv. 2011;4(10):1057-1066.
17. Forgione MA, et al. Cellular glutathione peroxidase deficiency and endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2002;282(4):H1255-H1261.
18. Oelze M, et al. Glutathione peroxidase-1 deficiency potentiates dysregulatory modifications of endothelial nitric oxide synthase and vascular dysfunction in aging. Hypertension. 2014;63(2):390-396.
19. Oguri M, et al. Genetic risk for restenosis after coronary stenting. Atherosclerosis. 2007;194(2):e172-e178.
20. Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta. 2009;1795(1):37-52.
21. Rikova K, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190-1203.
22. Lu SC. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J. 1999;13(10):1169-1183.
23. Keilhack H, et al. Negative regulation of Ros receptor tyrosine kinase signaling. An epithelial function of the SH2 domain protein tyrosine phosphatase SHP-1. J Cell Biol. 2001;152(2):325-334.
24. Charest A, et al. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res. 2006;66(15):7473-7481.
25. Chen C-Y, Willard D, Rudolph J. Redox regulation of SH2-domain-containing protein tyrosine phosphatases by two backdoor cysteines. Biochemistry. 2009;48(6):1399-1409.
26. Tanner JJ, Parsons ZD, Cummings AH, Zhou H, Gates KS. Redox regulation of protein tyrosine phosphatases: structural and chemical aspects. Antioxid Redox Signal. 2011;15(1):77-97.
27. Östman A, Frijhoff J, Sandin A˚, Böhmer F-D. Regulation of protein tyrosine phosphatases by reversible oxidation. J Biochem. 2011;150(4):345-356.
28. Joner M, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193-202.
29. Ashley EA, et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res. 2005;65(1):73-82.
30. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003;361(9374):2017-2023.
31. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347(9004):781-786.
32. Hu YJ, Diamond AM. Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the resonse to selenium. Cancer Research. 2003;63(12):3347-3351.
33. Suehara Y, et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clinical Cancer Research. 2012;18(24):6599-6608.
34. Lee H, et al. ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms. Ann Surg Oncol. 2013;20(1):200-208.
35. Zhao J-F, Sharma S. Expression of the ROS1 oncogene for tyrosine receptor kinase in adult human meningiomas. Cancer Genet Cytogenet. 1995;83(2):148-154.
36. Charest A, et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer. 2003;37(1):58-71.
37. Gu TL, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One. 2011;6(1):e15640.
38. Lee J, et al. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer. 2013;119(9):1627-1635.
39. Su AI, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A. 2004;101(16):6062-6067.
40. Finn AV, et al. Pathological correlates of late drug-eluting stent thrombosis. Circulation. 2007;115(18):2435-2441.
41. Nakazawa G, et al. The pathology of neoatherosclerosis in human coronary implants baremetal and drug-eluting stents. J Am Coll Cardiol. 2011;57(11):1314-1322.
42. Schlaeger TM, et al. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci U S A. 1997;94(7):3058-3063.
43. Shannon P, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-2504.
44. Baker MA, Cerniglia GJ, Zaman A. Microtiter plate assay for the measurement of glutathione and glutathione disulfide in large numbers of biological samples. Anal Biochem. 1990;190(2):360-365.
45. Chun HJ, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest. 2008;118(10):3343-3354.
46. Perez VA, et al. BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways. J Cell Biol. 2011;192(1):171-188.
47. Ali ZA, et al. CCR2-mediated antiinflammatory effects of endothelial tetrahydrobiopterin inhibit vascular injury-induced accelerated atherosclerosis. Circulation. 2008;118(14 suppl 1):S71-S77.
48. Adachi T, et al. S-glutathiolation of Ras mediates redox-sensitive signaling by angiotensin II in vascular smooth muscle cells. J Biol Chem. 2004;279(28):29857-29862.
49. Grosdidier A, Zoete V, Michielin O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res. 2011;39(suppl 2):W270-W277.
50. Hess B, Kutzner C, van der Spoel D, Lindahl E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput. 2008;4(3):435-447.
51. Bernard B, Samudrala R. A generalized knowledge-based discriminatory function for biomolecular interactions. Proteins. 2009;76(1):115-128.
52. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, Witten IH. The WEKA data mining software: an update. SIGKDD Explor Newsl. 2009;11(1):10-18.
53. Mechanic LE, Luke BT, Goodman JE, Chanock SJ, Harris CC. Polymorphism Interaction Analysis (PIA): a method for investigating complex gene-gene interactions. BMC Bioinformatics. 2008;9:146.
54. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26(17):2190-2191.